Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAXI for Lateral Canthal Lines
NCT03911102Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daxibotulinumtoxinA in lateral canthal rhytides (4 arms), sponsored by Revance Therapeutics. Primary endpoint: Percentage of Participants With None or Mild in LCL Severity at Maximum Smile at Week 4. Started Mar 2019; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT03911102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911102.